PriceTargets.com logo

Cypherpunk Technologies - CYPH Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $3.38
  • Forecasted Upside: 165.75%
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.27 As of 12/4/2025 05:00 PM ET
▼ -0.04 (-3.05%)

This chart shows the closing price for CYPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cypherpunk Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYPH

Analyst Price Target is $3.38
▲ +165.75% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Cypherpunk Technologies in the last 3 months. The average price target is $3.38, with a high forecast of $5.50 and a low forecast of $1.25. The average price target represents a 165.75% upside from the last price of $1.27.

This chart shows the closing price for CYPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 4 polled investment analysts is to reduce stock in Cypherpunk Technologies. This rating has held steady since September 2025, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
3/27/2025HC WainwrightReiterated RatingNeutral ➝ Neutral
1/29/2025Baird R WDowngradeStrong-Buy ➝ Hold
1/29/2025HC WainwrightDowngradeBuy ➝ Neutral
1/29/2025Robert W. BairdDowngradeOutperform ➝ Neutral$9.00 ➝ $1.25
1/16/2025HC WainwrightReiterated RatingBuy ➝ Buy$5.50 ➝ $5.50
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.50 ➝ $5.50
8/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.50 ➝ $5.50
6/28/2024Rodman & RenshawInitiated CoverageBuy$8.00
5/14/2024HC WainwrightLower TargetBuy ➝ Buy$7.00 ➝ $5.50
3/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00
3/19/2024Robert W. BairdLower TargetOutperform ➝ Outperform$11.00 ➝ $9.00
11/20/2023MizuhoLower TargetBuy ➝ Buy$20.00 ➝ $12.00
11/14/2023Raymond James FinancialLower TargetOutperform ➝ Outperform$18.50 ➝ $17.50
8/15/2023HC WainwrightBoost TargetBuy ➝ Buy$7.00
8/15/2023Robert W. BairdLower TargetOutperform ➝ Outperform$30.00 ➝ $20.00
6/23/2023Raymond James FinancialLower Target$20.00 ➝ $17.00
4/13/2023MizuhoReiterated RatingBuy$20.00
3/17/2023MizuhoLower TargetBuy$30.00 ➝ $20.00
1/27/2023MizuhoLower TargetBuy$60.00 ➝ $30.00
1/18/2023HC WainwrightLower TargetBuy$40.00 ➝ $25.00
1/17/2023Piper SandlerLower Target$40.00 ➝ $30.00
11/21/2022Robert W. BairdLower Target$40.00
11/11/2022Raymond James FinancialLower TargetOutperform$35.00 ➝ $25.00
8/15/2022Raymond James FinancialBoost TargetOutperform$30.00 ➝ $35.00
7/13/2022Raymond James FinancialLower TargetOutperform$40.00 ➝ $30.00
5/27/2022Piper SandlerLower Target$60.00 ➝ $40.00
11/15/2021HC WainwrightReiterated RatingBuy$40.00
10/22/2021MizuhoReiterated RatingBuy$60.00
10/4/2021MizuhoInitiated CoverageBuy$60.00
9/13/2021Raymond James FinancialBoost TargetOutperform$30.00 ➝ $40.00
5/17/2021Piper SandlerLower TargetOverweight$60.00 ➝ $40.00
3/23/2021Raymond James FinancialSet TargetOutperform$35.00
3/15/2021Raymond James FinancialSet TargetOutperform$35.00
3/2/2021Raymond James FinancialBoost TargetOutperform$25.00 ➝ $35.00
12/23/2020Raymond James FinancialSet TargetOutperform$25.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 1 very positive mentions
  • 29 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 1 very positive mentions
  • 29 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Cypherpunk Technologies logo
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.27
Low: $1.21
High: $1.42

50 Day Range

MA: $1.01
Low: $0.35
High: $2.97

52 Week Range

Now: $1.27
Low: $0.22
High: $3.70

Volume

6,160,973 shs

Average Volume

68,725,312 shs

Market Capitalization

$52.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Cypherpunk Technologies?

The following Wall Street analysts have issued stock ratings on Cypherpunk Technologies in the last twelve months: Baird R W, HC Wainwright, Robert W. Baird, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for CYPH.

What is the current price target for Cypherpunk Technologies?

0 Wall Street analysts have set twelve-month price targets for Cypherpunk Technologies in the last year. Their average twelve-month price target is $3.38, suggesting a possible upside of 165.7%. HC Wainwright has the highest price target set, predicting CYPH will reach $5.50 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $1.25 for Cypherpunk Technologies in the next year.
View the latest price targets for CYPH.

What is the current consensus analyst rating for Cypherpunk Technologies?

Cypherpunk Technologies currently has 1 sell rating and 3 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for CYPH.

What other companies compete with Cypherpunk Technologies?

Other companies that are similar to Cypherpunk Technologies include Precision BioSciences, Journey Medical, Eupraxia Pharmaceuticals, Sagimet Biosciences and Quince Therapeutics. Learn More about companies similar to Cypherpunk Technologies.

How do I contact Cypherpunk Technologies' investor relations team?

Cypherpunk Technologies' physical mailing address is 47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 USA. The company's listed phone number is (617) 714-0360 and its investor relations email address is [email protected]. The official website for Cypherpunk Technologies is www.leaptx.com. Learn More about contacing Cypherpunk Technologies investor relations.